Ret Proto-Oncogene anticorps

N° du produit ABIN498621

Détail du produit anti-Ret Proto-Oncogene anticorps

Antigène: Ret Proto-Oncogene (RET)

Reactivité: Humain, Souris, Rat

Hôte: Lapin

Clonalité: Polyclonal

Conjugué: Cet anticorp Ret Proto-Oncogene est non-conjugé

Application: Western Blotting (WB)

Specificité: This antibody detects endogenous levels of Ret protein. (region surrounding Trp1056)

Réactivité croisée (Details): Species reactivity (expected):Mouse and Rat.
Species reactivity (tested):Human.

Purification: Affinity chromatography using epitope-specific immunogen

Pureté: > 95 % (by SDS-PAGE)

Information d'application

Indications d'application: Western blot: 1: 500 - 1: 1000.
Other applications not tested.
Optimal dilutions are dependent on conditions and should be determined by the user.

Restrictions: For Research Use only

Stockage

Concentration: 1.0 mg/mL

Buffer: Phosphate buffered saline (PBS), pH 7.2, 0.05 % sodium azide

Agent conservateur: Sodium azide

Précaution d'utilisation: This product contains sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Conseil sur la manipulation: Avoid repeated freezing and thawing.

Stock: 4 °C/-20 °C

Stockage commentaire: Store at 2 - 8 °C for up to one month or (in aliquots) at -20 °C for longer.

Détails sur Ret Proto-Oncogene

Antigène: Ret Proto-Oncogene (RET)

Autre désignation: RET (RET Produits)

Synonymes: anticorps c-ret, anticorps cret, anticorps etID315074.13, anticorps ret1, anticorps wu:fd13h01, anticorps X-ret, anticorps ret-A, anticorps xret, anticorps RET, anticorps MTC1, anticorps CDHF12, anticorps CDHR16, anticorps HSCR1, anticorps MEN2A, anticorps MEN2B, anticorps PTC, anticorps RET-ELE1, anticorps RET51, anticorps RET9, anticorps c-Ret, anticorps ret proto-oncogene receptor tyrosine kinase, anticorps ret proto-oncogene S homeolog, anticorps ret proto-oncogene, anticorps ret, anticorps ret.S, anticorps RET, anticorps Ret

Sujet: The Ret proto-oncogene is structurally related to the growing family of tyrosine kinase transmembrane receptors and is involved in GDNF signaling. By alternative splicing, two isoforms of the Ret proto-oncogene product are generated. The isoforms differ from each other by having either 9 or 51 carboxy terminal amino acids. The Ret gene products include two glycosylated proteins in tunicamycin treated cells, a non-glycosylated protein consistent with the predicted Ret molecular weight based on sequence analysis. Tumorspecific rearrangements of the Ret proto-oncogene have been identified in papillary thyroid carcinomas leading to the formation of different transforming fusion proteins sharing the tyrosine kinase domain of Ret. In contrast to the Ret proto-oncogene, the rearranged forms are constitutively phosphorylated on tyrosine and are translocated from the membrane to the cytoplasm.Synonyms: C-ret, CDHF12, Cadherin family member 12, Proto-oncogene tyrosine-protein kinase receptor ret

Poids moléculaire: approx. 175 kDa

ID gène: 5979

NCBI Accession: NP_066124

UniProt: P07949

Pathways: Signalisation RTK, Dopaminergic Neurogenesis, Regulation of Cell Size, Tube Formation